Bringing a significant clinical breakthrough to the 2024 RSNA Annual Meeting, AGFA HealthCare is thrilled to announce a groundbreaking partnership with CARPL.ai, the leading radiology AI marketplace. This collaboration aims to revolutionize radiology practice through seamless integration and enhanced flexibility.

Unlock the Potential of Radiology with AGFA and CARPL.ai

From Complexity to Simplicity: Centralizing AI for Scalable Success

Adopting AI at scale poses challenges for care providers due to a fragmented ecosystem. However, a unified platform approach offers a solution by consolidating diverse clinical use cases and AI algorithms. The CARPL platform provides streamlined access and integration capabilities, unlocking exponential value for healthcare providers. It allows them to harness the full potential of AI across multiple clinical domains and drive transformative improvements in patient care.For example, RUBEE® for AI powered by the CARPL Platform automates tasks, enhances visualization, and simplifies workflows. Clinicians can spend less time navigating systems and more time focusing on their patients. By integrating AI into existing tools, healthcare organizations can unlock the true value of their AI investments, leading to faster diagnoses, more efficient workflows, and improved care delivery.

Bringing Two Worlds Together: Radiologists Leveraging the Ecosystem

This partnership brings together two worlds, enabling radiologists to leverage the encapsulated value of the entire ecosystem. AGFA HealthCare Chief Medical Officer Dr. Anjum Ahmed emphasizes the significance of this integration. Instead of adding complexity, RUBEE® seamlessly integrates advanced AI capabilities into providers' existing Enterprise Imaging ecosystem. It works with the tools they trust, bringing powerful AI-driven insights into their everyday workflow without extra steps or new systems.The RUBEE® AI powered by the CARPL Platform enables a marketplace ecosystem that helps customers scale up and expand based on their clinical requirements. Customers have the flexibility to choose from RUBEE® AI Packages and RUBEE® Integrations depending on their unique AI needs.

Collaboration for Radiology's Future: Empowering Care Providers

Vidur Mahajan, CEO of CARPL.ai, highlights the importance of this collaboration. As the first and only FDA-cleared AI marketplace, CARPL aims to democratize access to AI for radiologists. The partnership with AGFA HealthCare allows radiologists to have the entire AI ecosystem at their fingertips and validate/monitor AI applications. This will enable them to exponentially improve clinical and operational care for their patients.Dr. Anjum Ahmed is delighted to support this partnership and has committed to an RSNA AI theatre session. Entitled "PACS as a gateway to AI – how leading PACS providers are partnering with CARPL to AI enable their users," the session showcases the collaboration and takes place on Monday, 2 December at 2.30pm CST in the AI Theatre in the South Hall.AGFA HealthCare reaffirms its commitment to advancing radiology practice through Enterprise Imaging. At RSNA 2024, their next-generation technology will demonstrate "Grow, Work, Life – in Balance; how they break down imaging barriers, drive professional growth, promote work-life balance, and empower radiology networks with intelligent, seamless connections.About AGFA HealthCareAt AGFA HealthCare, we are dedicated to transforming the delivery of care. Our value framework of Mission, Vision, and Customer Delivery Principles guides our routine operations and ensures a consistent high-yield code of conduct for our associates. Through the power of technology, we create an exceptional experience for healthcare professionals worldwide. AGFA HealthCare is a division of the Agfa-Gevaert Group. For more information, visit www.agfahealthcare.com.AGFA and the Agfa rhombus are registered trademarks of Agfa-Gevaert N.V. Belgium or its affiliates. RUBEE® is a registered trademark of AGFA HealthCare NV or its affiliates. All rights reserved. All information contained herein is intended for guidance purposes only, and the characteristics of the products and services described in this publication can be changed at any time without notice. Products and services may not be available for your local area. Please contact your local sales representative for availability information. AGFA HealthCare diligently strives to provide as accurate information as possible but shall not be responsible for any typographical error.About CARPL.aiCARPL is an enterprise imaging platform that enables radiologists to build, test, deploy, and monitor AI in clinical workflows. It boasts the world's largest AI marketplace* with 140+ apps from 65+ vendors, giving radiologists the power to choose the right AI. It is the only FDA-cleared and CE-marked AI platform, with a universal AI widget for seamless and intuitive use. It is trusted by the world's largest and most prestigious radiology groups, such as Massachusetts General Hospital, University Hospitals (Cleveland), RadNet, and I-MED radiology.Contact InformationBuse Kayar: buse.kayar@issuerdirect.comJessica Baldry: Global Marketing & Communications Manager, AGFA HealthCare; jessica.baldry@agfa.com; +44 7583 203971Source: AGFA HealthCare

In this comprehensive exploration, we delve into the world of healthcare stocks that hold significant growth potential. As the global healthcare landscape continues to evolve, these 10 stocks stand out as promising investment opportunities. Let's take a closer look at each one and uncover the reasons behind their growth.

Unlock the Potential of High Growth Healthcare Stocks

1. Globus Medical, Inc. (NYSE:GMED)

Globus Medical, Inc. (NYSE:GMED) is a prominent player in the medical device industry, specializing in cutting-edge musculoskeletal solutions. Their innovative implants, surgical instruments, and advanced technologies have positioned them at the forefront of spine and orthopedic procedures. With a remarkable five-year average revenue growth of over 26%, GMED is a true gem in the healthcare sector.The Excelsius GPS robotic system and the integration of NuVasive’s Pulse platform have given Globus Medical a technological edge. In Q3 2024, the company witnessed a stunning 63.1% year-over-year revenue surge, reaching $626 million. This growth was driven by a 60.3% increase in U.S. sales and a 74.8% rise in international sales. GAAP EPS soared by an astonishing 3700%, thanks to the transformative acquisition of NuVasive, which expanded their market presence and product portfolio.The company is focused on enhancing manufacturing efficiencies and preparing for insourcing to achieve significant cost savings in the coming years. On the R&D front, GMED launched four new products, including the Excelsius Navigation Hub, their first freehand navigation solution.As of the end of Q3 2024, 36 hedge funds held stakes in Globus Medical. Sculptor Capital emerged as the largest stakeholder, with investments valued at $1.6 billion. Street analysts have assigned a consensus rating of Moderate Buy to the stock, with an average price target of $89.20, ranging from $80.00 to $100.00, indicating a potential 6.71% upside from its current price of $83.59.

2. Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a biopharmaceutical powerhouse dedicated to developing treatments for neurological, endocrine, and psychiatric disorders. Their flagship product, Ingrezza (valbenazine), is widely used in the treatment of tardive dyskinesia and chorea associated with Huntington’s diseases.The company’s pipeline is robust, featuring diverse treatments at various stages of development. Highlights include Crinecerfont, which recently received Breakthrough Therapy designation for congenital adrenal hyperplasia (CAH), with a New Drug Application planned for 2024. NBI-‘770, an oral NMDA NR2B negative allosteric modulator, is in Phase 2 trials for major depressive disorder. Additionally, Neurocrine Biosciences has the largest portfolio of muscarinic compounds in clinical development, including NBI-‘568 for schizophrenia.To ensure long-term growth, Neurocrine Biosciences is diversifying its portfolio through different modalities, such as small molecules, biologics, and gene therapies. The company aims to advance two gene therapies into clinical trials by 2025 and have at least 20 development candidates by 2027, creating numerous opportunities for innovation and reducing the risks associated with drug development.In Q3 2024, Ingrezza sales reached $613 million, contributing to a raised full-year guidance of $2.3 to $2.32 billion, representing a 25% year-over-year growth at the midpoint. The company has announced a $300 million share repurchase plan, demonstrating confidence in its valuation and future growth prospects.Street analysts have a consensus Strong Buy rating on the stock. The average 12-month price target is $166.53, with a high of $192.00 and a low of $121.00, suggesting a 35.07% upside potential.

3. Insmed Incorporated (NASDAQ:INSM)

Insmed Incorporated (NASDAQ:INSM) is a global biopharmaceutical company committed to developing and commercializing life-changing therapies for patients with serious and rare diseases. Their focus is on areas with high unmet medical needs, particularly in rare pulmonary disorders and neutrophil-mediated inflammatory diseases.In the third quarter, Insmed reported total revenues of $93.4 million, representing an 18% year-over-year increase. This growth was primarily driven by the marketed drug, Arikayce, which saw increased demand across all regions. However, the company posted a net loss of $220.5 million, or $1.27 per share, which was wider than the previous year’s loss of $158.9 million ($1.11 per share). Research and development (R&D) expenses rose by 38% to $150.8 million, and selling, general, and administrative (SG&A) expenses increased by 31% to $118.9 million compared to the same period last year.Insmed is gearing up for the potential launch of Brensocatib in mid-2025 and plans to submit a New Drug Application (NDA) to the FDA in Q4 2024. As of Q3 2024, 67 hedge fund holders had stakes in the company, with Darwin Global Management being the largest stakeholder, holding worth $766,301,221.Street analysts have a consensus Strong Buy rating on Insmed Incorporated, making it one of the top high growth stocks to invest in.